Vivek Subbiah: A study in the United States, Canada, & Germany using retrospective real-world databases
Vivek Subbiah, made the following post on Twitter:
“Hot off the press: Pleased to share our paper: Association between treatment and improvements in overall survival of patients with advanced/metastatic non–small cell lung cancer since 2011: A study in the United States, Canada, & Germany using retrospective real-world databases”
For details click here.
Source: Vivek Subbiah/Twitter
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute. He is the former Executive Director of Oncology Research at the MD Anderson Cancer Network and a former Associate Professor in the Department of Investigational Cancer Therapeutics at The University of Texas MD Anderson Cancer Center. Dr. Subbiah’s research interests include drug development in rare cancers, immunotherapy, and radiopharmaceuticals.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023